Screener
Ligand Pharmaceuticals LGND Net gains (losses) on investments
Net gains (losses) on investments at other companies
Other financials
Where this comes from
Reported directly by Ligand Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:UnrealizedGainLossOnInvestments.
The source filing: Ligand Pharmaceuticals’s 10-Q, filed August 7, 2026.
- Filed
- Aug 7, 2026, 4:06 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0000886163-26-000044
| Supplemental disclosure of cash flow information: | ||
|---|---|---|
| Interest paid | $$2,369 | 201 |
| Taxes paid | $$3,313 | 4,554 |
| Supplemental schedule of non-cash investing and financing activities: | ||
| Addition of right-of-use assets and lease liabilities | — | 2,315 |
| Accrued debt issuance costs | $$906 | — |
| Accrued fixed asset purchases | $$44 | 9 |
| Unrealized loss on available-for-sale investments, net of tax | $$(754) | (71) |
Item 1. Condensed Consolidated Financial Statements (unaudited)
FAQ
- What is Ligand Pharmaceuticals's net gains (losses) on investments?
- Ligand Pharmaceuticals (LGND) reported net gains (losses) on investments of -$22K in Q2 2026.
- How has Ligand Pharmaceuticals's net gains (losses) on investments changed year-over-year?
- Ligand Pharmaceuticals's net gains (losses) on investments increased by 55.1% year-over-year, from -$49K to -$22K.
- What is the long-term trend for Ligand Pharmaceuticals's net gains (losses) on investments?
- Over 2 years (2021 to 2025), Ligand Pharmaceuticals's net gains (losses) on investments has grown at a -9.5% compound annual growth rate (CAGR), from -$221K to $181K.
- What does net gains (losses) on investments mean?
- Realized and unrealized gains/losses on investments removed from operating cash flow since they're investing-related.
Ask your AI about Ligand Pharmaceuticals's net gains (losses) on investments.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude